Related Experiment Video

Updated: Jul 1, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

857

Platelet Function Testing to Guide Cangrelor Dosing in Patients with Temporary Mechanical Circulatory Support or as a

Margaret M Buck1, Chelsea I Barry2, Courtney A Montepara2,3

  • 1Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|March 5, 2024
PubMed

Insights

Platelet function testing (PFT) guided cangrelor dosing in high-risk patients reduced costs and maintained efficacy. This approach prevented stent thrombosis while allowing for individualized medication levels.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Cangrelor is an intravenous P2Y12 inhibitor used post-percutaneous coronary intervention (PCI), particularly in patients needing mechanical circulatory support or as a bridge to procedures.
  • Optimal dosing of cangrelor is crucial for balancing efficacy (preventing stent thrombosis) and safety (minimizing bleeding).

Purpose of the Study:

  • To evaluate the effectiveness and safety of using platelet function testing (PFT) to guide cangrelor dosing in adult patients.
  • To assess the impact of PFT-guided dosing on clinical outcomes, including stent thrombosis and major adverse cardiovascular events.
  • To determine the cost-effectiveness of individualized cangrelor dosing based on PFT results.

Main Methods:

  • A retrospective review of adult patients who received PFT (VerifyNow P2Y12 assay) while on cangrelor treatment from March 2021 to November 2022.
  • Patients were initiated on a standard cangrelor dose (0.75 mcg/kg/min), with subsequent dose adjustments based on P2Y12 reaction unit (PRU) values to maintain a therapeutic range of 85-208.
  • Data collected included cangrelor doses, PRU values, time in therapeutic range, and clinical outcomes such as stent thrombosis, major adverse cardiovascular events, and bleeding.

Main Results:

  • Out of 42 patients, 90.5% required mechanical circulatory support and 9.5% received cangrelor as a bridge to procedure.
  • The median maintenance cangrelor dose was 0.5 mcg/kg/min, with a median of 66.6% of patients achieving the target PRU range (85-208).
  • No cases of stent thrombosis were reported. Major bleeding occurred in 38.1% of patients. PFT-guided dosing resulted in a median drug cost saving of $1605.60 compared to empiric dosing.

Conclusions:

  • Platelet function testing-guided cangrelor dosing is a viable strategy for managing high-risk cardiovascular patients.
  • This individualized approach effectively prevents stent thrombosis and may lead to significant cost savings.
  • Further research into PFT-guided cangrelor therapy can optimize patient care and resource utilization.

Keywords:
P2Y12 reaction unitantiplateletsbridgingextracorporeal membrane oxygenationimpella

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

238
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.0K

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523